Morepen Labs Baddi facility clears USFDA inspection without any adverse observation
Gurugram: Morepen Labs has recently announced that the United States Food and Drug Administration (USFDA) has conducted an inspection of the API manufacturing facility, at Baddi, Himachal Pradesh, of the company.
"The facility has been cleared by USFDA on 24th March 2023 without any adverse observation (NIL 483)," the company stated in a BSE filing.
Read also: Morepen Labs forms new subsidiary for medical devices
Morepen Labs is a pharmaceutical company headquartered in New Delhi. The company was founded in 1984. With a strong global presence, Morepen exports to over 75 countries with certifications from all major regulatory authorities like USFDA, WHO GMP, EU GMP.
Next Story
